跳至主要内容
临床试验/NCT01990911
NCT01990911已完成不适用

Renal Sympathetic Denervation Restores Autonomic Imbalance and Prevents Atrial Fibrillation in Patients With Hypertensive Heart Disease: a Pilot Study

Pace Clinic1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2013年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
80
试验地点
1
主要终点
Atrial fibrillation

研究概览

简要总结

The autonomic nervous system plays an important role in the precipitation of AF in structurally-abnormal hearts. Restoration of autonomic imbalance may therefore prevent new-onset AF.

Renal artery denervation (RDN) is a novel percutaneous procedure that uses radio-frequency energy to destroy the sympathetic renal nerves. Symplicity 1 and -2 studies have shown that RDN effectively reduces blood pressure in up to 80% of treated patients. LVH regression and improvement of diastolic dysfunction follow as a consequence of afterload reduction and renin-angiotensin-aldosterone system modulation. RDN may thus also reduce intra-atrial pressure resulting in less stretch of the pulmonary venous ostia where most ectopic AF-foci originate.

Hypothesis: RDN restores autonomic imbalance in HTHD and lowers intra-atrial pressure by reducing afterload. These synergistic mechanisms may prevent new-onset AF.

详细描述

One hundred consenting patients meeting all inclusion criteria will undergo an exercise stress test, 2D and M-Mode echocardiograms and 24-hour ambulatory blood pressure holter monitoring prior to being randomised to receive either renal denervation (RDN) with a Symplicity renal denervation catheter plus medical therapy or medical therapy alone. Coronary angiography with/without coronary revascularisation will be performed as per the treating cardiologist's clinical judgement and a Reveal® holter will be implanted in all patients at the end of the procedure.

Time zero will be defined as starting at three months after the procedure. Follow up visits will be scheduled to scan the holter for the primary end point, i.e. high atrial rates (AF-surrogate defined as: "episodes of atrial rate >190 beats per minute for more than 6 minutes") or new-onset AF. Patients will be followed six monthly for three years.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Single (Participant)

入排标准

年龄范围
55 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Must have an indication for coronary angiography e.g.
  • Acute coronary syndrome
  • Positive stress ECG: - Defined as ≥1mm ST segment shift (depression or elevation) in ≥2 contiguous leads with/without chest discomfort)
  • Age ≥55 years
  • Office blood pressure ≥160/90mmHg in non-diabetics or ≥150/90mmHg in diabetics
  • Subjects must be on at least 3 anti-hypertensive drugs, including a diuretic agent
  • Sinus rhythm
  • Left ventricular hypertrophy defined on echo as:
  • Estimated LV mass > 255 g or LVMI >131 g/m2 for men
  • Estimated LV mass >193 g or LVMI >113 g/m2for women
  • Left atrial diameter ≥45mm on any echocardiographic window

排除标准

  • Estimated glomerular filtration rate (eGFR) < 45ml/min/1.73m2
  • Renal artery anatomy unsuitable for RDN
  • Substantial stenotic valvular heart disease
  • Pregnancy or planned pregnancy
  • Thyrotoxicosis
  • Patients needing to undergo coronary artery bypass surgery

研究组 & 干预措施

Renal denervation

Experimental

Renal denervation: both renal arteries are denervated by applying radio-frequency energy at application points moving in a helical fashion starting in the distal renal artery and moving to the proximal junction with the abdominal aorta.

干预措施: Renal denervation (Device)

Renal denervation

Experimental

Renal denervation: both renal arteries are denervated by applying radio-frequency energy at application points moving in a helical fashion starting in the distal renal artery and moving to the proximal junction with the abdominal aorta.

干预措施: Medical therapy (Drug)

Medical therapy

Sham Comparator

This group will not receive renal sympathetic denervation

干预措施: Medical therapy (Drug)

结局指标

主要结局

Atrial fibrillation

时间窗: 3 years

Subclinical atrial tachyarrhythmias (episodes of atrial rate \>190 beats per minute for more than 6 minutes) or atrial fibrillation recorded by implantable loop recorder (Reveal® holter).

次要结局

  • Restoration of autonomic imbalance(3 years)

研究者

发起方
Pace Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Marshall Jacobus Heradien

Dr

Pace Clinic

研究点 (1)

Loading locations...

相似试验